Identifying and navigating bottlenecks in the translation of novel radiopharmaceuticals: a perspective.
作者信息
Schottelius Margret
机构信息
Translational Radiopharmaceutical Sciences, Depts. of Nuclear Medicine and of Oncology, Centre Hospitalier Universitaire Vaudois (CHUV), University of Lausanne (UNIL), Lausanne, Switzerland.
Agora, pôle de recherche sur le cancer, Lausanne, Switzerland.
出版信息
Eur J Nucl Med Mol Imaging. 2025 Feb;52(3):796-800. doi: 10.1007/s00259-024-07020-1.
Abstract
摘要
相似文献
1
Identifying and navigating bottlenecks in the translation of novel radiopharmaceuticals: a perspective.识别和突破新型放射性药物翻译过程中的瓶颈：一种观点
Eur J Nucl Med Mol Imaging. 2025 Feb;52(3):796-800. doi: 10.1007/s00259-024-07020-1.
2
Practical considerations for navigating the regulatory landscape of non-clinical studies for clinical translation of radiopharmaceuticals.放射性药物临床转化非临床研究监管环境的实际考量
EJNMMI Radiopharm Chem. 2022 Jul 19;7(1):18. doi: 10.1186/s41181-022-00168-x.
3
Chemistry Considerations for the Clinical Translation of Oncology PET Radiopharmaceuticals.肿瘤 PET 放射性药物临床转化的化学考虑因素。
Mol Pharm. 2020 Jul 6;17(7):2245-2259. doi: 10.1021/acs.molpharmaceut.0c00328. Epub 2020 Jun 5.
4
Radiopharmaceuticals: navigating the frontier of precision medicine and therapeutic innovation.放射性药物：探索精准医学与治疗创新的前沿。
Eur J Med Res. 2024 Jan 5;29(1):26. doi: 10.1186/s40001-023-01627-0.
5
Current status and future perspective of radiopharmaceuticals in China.中国放射性药物的现状和未来展望。
Eur J Nucl Med Mol Imaging. 2022 Jul;49(8):2514-2530. doi: 10.1007/s00259-021-05615-6. Epub 2021 Nov 12.
6
Radiopharmaceuticals for oncology drug development: a pharmaceutical industry perspective.肿瘤学药物研发中的放射性药物：制药行业视角
Curr Pharm Des. 2009;15(9):957-65. doi: 10.2174/138161209787581977.
7
Mechanisms of drug interactions between translation-inhibiting antibiotics.翻译抑制抗生素相互作用的机制。
Nat Commun. 2020 Aug 11;11(1):4013. doi: 10.1038/s41467-020-17734-z.
8
Clinical translation of theranostic radiopharmaceuticals: Current regulatory status and recent examples.诊疗用放射性药物的临床转化：当前监管状况及近期实例
J Labelled Comp Radiopharm. 2019 Aug;62(10):673-683. doi: 10.1002/jlcr.3712. Epub 2019 Mar 21.
9
Patterns in bottlenecks for implementation of health promotion interventions: a cross-sectional observational study on intervention-context interactions in the Netherlands.健康促进干预措施实施中的瓶颈模式：荷兰干预与背景互动的横断面观察研究
Arch Public Health. 2023 Oct 17;81(1):183. doi: 10.1186/s13690-023-01196-y.
10
Current Status and Perspectives of Novel Radiopharmaceuticals with Heterologous Dual-targeted Functions: 2013-2023.具有异源双靶向功能的新型放射性药物的现状与展望：2013 - 2023年
J Med Chem. 2024 Dec 26;67(24):21644-21670. doi: 10.1021/acs.jmedchem.4c01608. Epub 2024 Dec 8.
引用本文的文献
1
Multidimensional in silico evaluation of fluorine-18 radiopharmaceuticals: integrating pharmacokinetics, ADMET, and clustering for diagnostic stratification.氟-18放射性药物的多维计算机模拟评估：整合药代动力学、药物代谢及毒性预测和聚类分析用于诊断分层
J Comput Aided Mol Des. 2025 Sep 3;39(1):75. doi: 10.1007/s10822-025-00655-8.
本文引用的文献
1
Validation of the C-X-C chemokine receptor 3 (CXCR3) as a target for PET imaging of T cell activation.验证C-X-C趋化因子受体3（CXCR3）作为T细胞活化PET成像靶点的有效性。
EJNMMI Res. 2024 Aug 28;14(1):77. doi: 10.1186/s13550-024-01142-1.
2
Covalent targeted radioligands potentiate radionuclide therapy.共价靶向放射性配体增强放射性核素治疗。
Nature. 2024 Jun;630(8015):206-213. doi: 10.1038/s41586-024-07461-6. Epub 2024 May 22.
3
EANM guidance document: dosimetry for first-in-human studies and early phase clinical trials.EANM 指导文件：用于首次人体研究和早期临床试验的剂量学。
Eur J Nucl Med Mol Imaging. 2024 Apr;51(5):1268-1286. doi: 10.1007/s00259-024-06640-x. Epub 2024 Feb 17.
4
Pre-clinical evaluation of biomarkers for the early detection of nephrotoxicity following alpha-particle radioligand therapy.α 粒子放射性配体治疗后用于早期检测肾毒性的生物标志物的临床前评估。
Eur J Nucl Med Mol Imaging. 2024 Apr;51(5):1395-1408. doi: 10.1007/s00259-023-06559-9. Epub 2023 Dec 14.
5
Health-related quality of life and pain outcomes with [Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a multicentre, open-label, randomised, phase 3 trial.LuLu-PSMA-617 联合标准护理与标准护理治疗转移性去势抵抗性前列腺癌患者的健康相关生活质量和疼痛结局（VISION）：一项多中心、开放标签、随机、3 期临床试验。
Lancet Oncol. 2023 Jun;24(6):597-610. doi: 10.1016/S1470-2045(23)00158-4.
6
Use of imaging-based dosimetry for personalising radiopharmaceutical therapy of cancer.基于影像的剂量学在癌症放射性药物治疗个体化中的应用。
Cancer Imaging. 2022 Dec 9;22(1):67. doi: 10.1186/s40644-022-00505-y.
7
Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial.Lu-Dotatate 联合长效奥曲肽与高剂量长效奥曲肽治疗肠神经内分泌肿瘤患者（NETTER-1）：一项开放标签、随机、对照、III 期临床试验的最终总生存和长期安全性结果。
Lancet Oncol. 2021 Dec;22(12):1752-1763. doi: 10.1016/S1470-2045(21)00572-6. Epub 2021 Nov 15.
Zotero 插件